9-ING-41 in Patients With Advanced Cancers
← catalyst calendarSponsored by Actuate Therapeutics Inc. (industry) · ACTU — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
350estimated
Sites
66
Countries
Belgium, Canada, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-04 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2018-09-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Pancreatic Cancer
- Sarcoma
- Renal Cancer
- Refractory Cancer
- Refractory Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Pancreatic Adenocarcinoma
- Resistant Cancer
- Neoplasm Metastasis
- Neoplasm of Bone
- Neoplasm, Breast
- Neoplasm of Lung
- Neoplasms,Colorectal
- Neoplasms Pancreatic
- Malignant Glioma
- Malignancies
- Malignancies Multiple
- Bone Metastases
- Bone Neoplasm
- Bone Cancer
- Pancreas Cancer
- Pancreatic Neoplasms
- Breast Neoplasms
- Acute T Cell Leukemia Lymphoma
Interventions
- Drug: 9-ING-41
- Drug: Gemcitabine - 21 day cycle — also filed as Gemzar
- Drug: Doxorubicin. — also filed as Doxil, Adriamycin
- Drug: Lomustine — also filed as CCNU, Gleostine
- Drug: Carboplatin. — also filed as Paraplatin
- Drug: Nab paclitaxel. — also filed as Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel
- Drug: Paclitaxel. — also filed as Taxol
- Drug: Gemcitabine - 28 day cycle — also filed as Gemzar
- Drug: Irinotecan — also filed as Camptosar
Primary outcomes
what the primary-completion date above is the date OFParts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
measured 3 months to 3 years
Part 3 Arm B
measured 3 months to 3 years
Publications
- PMID 29846250 — reports results
- PMID 29383130 — reports results
- PMID 28672195 — reports results
- PMID 27424289 — reports results
- PMID 24327518 — reports results
- PMID 28053024 — reports results
- PMID 30405781 — reports results
- PMID 30975030 — reports results
- PMID 31101621 — reports results
- PMID 31533931 — reports results
- PMID 31831767 — reports results
- PMID 31882719 — reports results
- PMID 31894292 — reports results
- PMID 41981308 — linked by the registry
- PMID 35815408 — linked by the registry
- PMID 31401903 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ACTU's whole pipeline · Catalyst calendar · Every registered study · What changed